Table 3.
Univariate and Multivariate Analysis of Clinicopathologic Variables Associated with Overall Survival in 217 Patients with Major Pathologic Tumor Response to Preoperative Chemotherapy for CLM
| Variable | N (%) | 5-year Overall Survival Rate (%) | Univariate Analysis P | Multivariate Analysis*
|
|
|---|---|---|---|---|---|
| P | Hazard Ratio (95% CI) | ||||
| Sex | 0.134 | ||||
| Male | 122 (56) | 55 | |||
| Female | 95 (44) | 73 | |||
| Age | |||||
| ≥ 60 years | 95 (44) | 54 | 0.255 | ||
| < 60 years | 122 (56) | 72 | |||
| Body mass index | |||||
| > 30 kg/m2 | 73 (34) | 58 | 0.842 | ||
| ≤ 30 kg/m2 | 144 (66) | 66 | |||
| Timing of detection of CLM | |||||
| Synchronous | 151 (70) | 59 | 0.245 | ||
| Metachronous | 66 (30) | 72 | |||
| Primary tumor site | 0.035 | NS | |||
| Rectum | 52 (24) | 43 | |||
| Colon | 165 (76) | 68 | |||
| Regional lymph nodes for primary tumor | 0.036 | NS | |||
| Positive | 156 (72) | 57 | |||
| Negative | 61 (28) | 77 | |||
| Preoperative chemotherapy | 0.174 | ||||
| Irinotecan | 59 (27) | 68 | |||
| Oxaliplatin | 158 (73) | 61 | |||
| Preoperative cetuximab | 0.240 | ||||
| Yes | 13 (6) | 0 | |||
| No | 204 (94) | 66 | |||
| Preoperative bevacizumab | 0.310 | ||||
| Yes | 147 (68) | 57 | |||
| No | 70 (32) | 67 | |||
| No. of cycles of chemotherapy | 0.116 | ||||
| ≥ 6 | 130 (60) | 57 | |||
| < 6 | 87 (40) | 75 | |||
| Two-stage hepatectomy | 0.700 | ||||
| Yes | 19 (9) | 64 | |||
| No | 198 (91) | 64 | |||
| Portal vein embolization | 0.220 | ||||
| Yes | 26 (12) | 43 | |||
| No | 191 (88) | 67 | |||
| Associated procedure | 0.965 | ||||
| Yes | 31 (14) | 78 | |||
| No | 186 (86) | 63 | |||
| Major hepatectomy | 0.108 | ||||
| Yes | 149 | 59 | |||
| No | 68 | 76 | |||
| Major postoperative complications | 0.005 | 0.012 | 2.40 (1.21–4.76) | ||
| Yes | 32 (15) | 42 | |||
| No | 185 (85) | 68 | |||
| Blood transfusion | 0.093 | NS | |||
| Yes | 31 (14) | 43 | |||
| No | 186 (86) | 68 | |||
| Estimated blood loss | 0.850 | ||||
| > 1000 mL | 11 (5) | 48 | |||
| ≤ 1000 mL | 206 (95) | 65 | |||
| Number of CLM | 0.850 | ||||
| Multiple | 127 (58) | 60 | |||
| Single | 90 (42) | 69 | |||
| Maximum largest diameter of CLM | 0.312 | ||||
| ≥ 3 cm | 85 (39) | 62 | |||
| < 3 cm | 132 (61) | 64 | |||
| Preoperative CEA level | 0.939 | ||||
| ≥ 10 ng/mL | 34 (16) | 69 | |||
| < 10 ng/mL | 183 (84) | 63 | |||
| Margin status for resection of CLM | 0.587 | ||||
| R1 | 23 (11) | 67 | |||
| R0 | 194 (89) | 63 | |||
| Postoperative chemotherapy for CLM | 0.261 | ||||
| Yes | 153 (71) | 63 | |||
| No | 62 (29) | 62 | |||
*
Cox regression multivariate analysis included all variables with P < 0.1 in univariate analysis.
CEA indicates carcinoembryonic antigen; CLM, colorectal liver metastases; NS, not significant; R0, surgical margin ≥ 1 mm; R1, no margin or surgical margin < 1 mm.